Loading...
XSHE
000999
Market cap6.09bUSD
Oct 09, Last price  
24.82CNY
1D
1.39%
1Q
4.46%
Jan 2017
0.36%
IPO
22.27%
Name

China Resources Sanjiu Medical & Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:000999 chart
P/E
12.07
P/S
1.31
EPS
2.06
Div yield, %
2.84%
Shrs. gr., 5y
0.09%
Rev. gr., 5y
15.25%
Revenues
31.60b
+14.43%
4,316,186,8844,852,717,0394,365,153,3155,454,446,9616,943,465,7337,293,277,3967,276,585,5707,900,189,5628,981,721,07911,119,916,37913,427,746,16114,793,661,50513,637,258,15315,319,993,63415,544,401,73518,079,461,48218,079,461,48224,738,963,31927,616,611,77131,602,578,000
Net income
3.42b
+1.60%
500,086,807709,489,009815,984,768760,447,5661,021,088,9061,108,790,8241,035,889,0201,249,226,5381,197,840,6021,301,687,2541,432,078,2062,098,848,6371,597,489,1822,055,104,4072,055,104,4142,448,802,1032,448,802,1072,852,931,6713,367,888,9693,421,788,000
CFO
5.51b
+25.23%
425,505,881605,297,1941,116,375,222855,051,790848,277,111954,901,8951,211,832,6161,467,423,8251,184,427,7221,259,838,1831,392,140,6771,598,761,1231,911,246,8171,971,829,7662,223,984,7051,884,653,3443,006,375,0164,191,742,9494,402,199,3875,513,082,830
Dividend
May 29, 20260.59 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.

Key people

Chairman of the Board · since 2024
Chief Financial Officer, Secretary of the Board · since 2025
Chief Compliance Officer, Vice President, General Counsel, Director · since 2025
Yi Mai
Vice President · since 2015
Vice President · since 2024
Liang Wang
Vice President · since 2021
Vice President · since 2026
Vice President · since 2025
Xiaosong Bai
Director · since 2022
Xianfeng Huang
Staff Elected Director · since 2025
Zhuqiang Liang
Director · since 2024
President, Director · since 2025
Shutian Yu
Director · since 2022
Zhendan He
Independent Director · since 2024
Mengjuan Li
Independent Director · since 2024
Jian Sun
Independent Director · since 2024
Independent Director · since 2024
IPO date
Mar 09, 2000
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT